Novartis Recalls Excedrin Migraine Pouches Due to Incomplete Seals
Novartis is recalling 10.6 million Excedrin Migraine pouches because the packaging may not be fully sealed, potentially compromising product integrity.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation that might cause temporary or medically reversible adverse health consequences. The hazard is a packaging defect (incomplete seal) rather than a direct contamination or dosage error, fitting the Moderate severity criteria for low-risk contamination or packaging issues.
Plain-English summary
Novartis Consumer Health is recalling 10,624,000 pouches of Excedrin Migraine (Acetaminophen 250 mg, Aspirin 250 mg, and Caffeine 65 mg) and Excedrin Migrana. The recall affects 2-count tablets packaged in pouches distributed nationwide, in Puerto Rico, Brazil, and Panama.
The recall was initiated because the pouches may not have been fully sealed. This defect in the container could potentially affect the product's integrity. Specific lot numbers and expiration dates are listed in the official recall notice.
Consumers with these products should stop using them and contact Novartis Consumer Health for instructions on how to return the product or obtain a refund.
The recalled product
- Product
- Excedrin Migraine (Acetaminophen 250 mg, Aspirin (NSAID) 250 mg and Caffeine 65 mg), a) 2-count tablets packaged in pouches, Distributed by Novartis Consumer Health, Inc., Parsippany, NJ, NDC 0067 203 702 Foreign packaging: b) Excedrin Migrana (Acetaminophen 250 mg, Aspirin 2
- Manufacturer
- Novartis Consumer Health
- Affected units
- 10,624,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # a) 10116809
- Exp 5/13 Foreign: Lot #s b) 10115644 Exp 5/13
- 10118226 Exp 5/13
- 10118227 Exp 6/13
- 10118228 Exp 6/13
- 10121956 Exp 8/13 and 10121957 Exp 8/13
Distribution
Part of a larger recall action
This product is one of 4 recalled by Novartis Consumer Health under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Novartis Consumer Health
See all →- ModerateNovartis Recalls Benefiber Fiber Supplement Stick Packs Due to Consumer Complaints
FDA (Food) · 2014-03-05
- ModerateNovartis Recalls Theraflu Severe Cold & Cough Powder Packets for Foreign Substances
FDA (Drugs) · 2014-01-29
- HighNovartis Recalls Theraflu Powder Packets Due to Foreign Substance Presence
FDA (Drugs) · 2014-01-29
- ModerateNovartis Recalls NeoCitran Extra Strength Powder Packets Due to Foreign Substances
FDA (Drugs) · 2014-01-29
- ModerateNovartis Recalls Theraflu Exte Powder Packets Due to Foreign Substances
FDA (Drugs) · 2014-01-29
Same hazard · packaging defect
See all →- HighMD Wipe Outz Numbing Tattoo Wipes Recalled for Child Poisoning Risk
CPSC · 2026-08-27
- HighV-Loc 90 Absorbable Wound Closure Devices Recalled for Packaging Defects
FDA (Devices) · 2026-08-19
- SevereDermalon Sutures Recalled for Potential Sterile Barrier Packaging Defects
FDA (Devices) · 2026-08-19
- HighV-Loc 180 Absorbable Wound Closure Device Recalled for Packaging Defects
FDA (Devices) · 2026-08-19
- HighBiopsy Forceps Recall: Sterile Packaging Breach Risk
FDA (Devices) · 2026-08-12